A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease.

Trial Profile

A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Valsartan (Primary)
  • Indications Cardiovascular disorders; Heart failure; Hypertension; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Acronyms JIKEI-HEART
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Sep 2010 Results from an analysis of the effect of treatment on LVMI presented at the ESC Congress 2010: Annual Congress of the European Society of Cardiology
    • 01 Sep 2010 Results from an analysis of the effect of treatment on LVMI presented at the ESC Congress 2010: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top